Tipranavir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tipranavir: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Tipranavir (DB00932) is a non-peptidic HIV-1 protease inhibitor; this evidence pack does not carry a documented original indication or MOA (both flagged as data gaps), but the drug is broadly known as an antiretroviral for treatment-experienced HIV-1 infection. The TxGNN model's top-ranked prediction is Feline Acquired Immunodeficiency Syndrome (FIV), scored at 99.99%, but there are 0 clinical trials and 0 publications supporting this specific link, and the evidence pack itself notes that FIV protease differs structurally enough from HIV-1 protease that cross-inhibition is biologically unlikely — this is best read as a TxGNN embedding artifact, not a credible repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this dataset (drug-level original_indications/original_moa are data gaps); publicly known pharmacology: HIV-1 infection, treatment-experienced adults |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for tipranavir is marked as a data gap at the drug level in this evidence pack (DG002, High severity). Based on the mechanistic notes attached to the lower-ranked candidates in this same pack, tipranavir is a non-peptidic HIV-1 protease inhibitor that blocks viral replication by inhibiting protease-mediated cleavage of Gag-Pol polyproteins — but this is external/general knowledge, not something this dataset's drug-level fields actually support.
For the rank-1 prediction, FIV and HIV are both lentiviruses, which is presumably what drives the TxGNN embedding similarity. However, the evidence pack's own rationale explicitly flags that FIV protease and HIV-1 protease differ substantially in structure, and HIV protease inhibitors generally lack cross-species inhibitory activity against FIV protease. Combined with zero clinical trials, zero literature, and an evidence level of L5 (model prediction only), this specific top-ranked link should be treated as a low-confidence, likely spurious association rather than a genuine repurposing candidate.
Two lower-ranked candidates in this pack are mechanistically more coherent — "AIDS related complex" (rank 5) and "congenital human immunodeficiency virus" (rank 6) — since both sit within the HIV disease spectrum where protease inhibitors are an established drug class. Even so, the 9 trials retrieved for congenital HIV were graded "C" relevance because none actually studied tipranavir (they studied cabotegravir, dolutegravir, or general antiretroviral pharmacokinetics), so tipranavir-specific clinical evidence remains absent from this dataset for those indications too.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Tipranavir has 0 registered marketing authorizations in Finland (market status: 未上市 / not marketed), so no product-level table is available.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack; DG001 — TFDA/Fimea package insert — is flagged as a Blocking gap that prevents S1 safety screening.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (FIV, 99.99% score) has no supporting trials or literature, and the pack's own mechanistic review flags it as a likely cross-species embedding artifact rather than a real pharmacological link — evidence level L5 does not clear even preliminary screening.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain the TFDA/Fimea package insert to establish warnings/contraindications before any S1 safety evaluation.
- Resolve DG002 (High): confirm tipranavir's MOA via DrugBank API to properly assess mechanistic linkage.
- If pursuing HIV-spectrum indications instead of FIV, source tipranavir-specific trials/literature for "AIDS related complex" and "congenital HIV" (rank 5–6) — the trials currently attached to congenital HIV all involve other agents (cabotegravir, dolutegravir), not tipranavir itself.
- Treat rank 4 ("familial combined hyperlipidemia") as a candidate to exclude rather than pursue — the pack notes this likely reflects tipranavir's known dyslipidemia adverse-effect signal being mislearned as an indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.